Sharon presented our latest economic analysis report, 'Counting the Costs of CMV' outlining the economic cost of CMV in the UK. There was much interest in our findings and statistics and these were shared with other countries.
There were delegates from 16 different countries: USA, UK, Italy, Brazil, Canada, Sweden, China, Croatia, Belgium, France, South Africa, Australia, Japan, Germany, the Netherlands and Israel. So good to hear the interest and progress being made around the world.
Many talks centred on prevention and treatment, with presentations on vaccines from 4 pharmaceuticals - Merck, Moderna, City if Hope/Helocyte and Pfizer. Merck have completed phase 1 trials with adults with “no serious adverse events” which supports the move to phase 2, pregnant women, shortly. Moderna and Helocyte are at initial stages of 1st phase and Pfizer unfortunately reported a failure and their study has been halted.